LEXX - Multiplikator Forward P/S Lexaria Bioscience Corp
Precise transportation of compounds for clinical trials ensures therapy safety, which is reflected in the price action of Lexaria Bioscience (LEXX). The company's forward P/S ratio demonstrates the impact of raw material procurement optimization on operating profit. The seamless shipment of small samples for licensing supports stability, while the value of 46.80 serves as the current indicator for this metric, linking market capitalization to expected revenue.
Rincian metrik komprehensif lan analitis lexariabioscience.com (LEXX)
- rega pasar lan target rega analis:
- statistik kapitalisasi pasar:
- statistik nilai buku emiten:
- data utang lan likuiditas:
Utang marang Ekuitas Lexaria Bioscience|LEXX - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal Lexaria Bioscience Corp.|LEXX - Gunggung kewajiban utang perusahaan|Utang-utang marang kapitalisasi buku Lexaria Bioscience Corp.|LEXX - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Lexaria Bioscience|Rasio cepet lexariabioscience.com
- indikator pendapatan resik lan kelipatan nilai:
LEXX - Bathi resik perusahaan|Proyeksi bathi mangsa ngarep Lexaria Bioscience|LEXX - Periode bali modal bisnis|Rega marang bathi mangsa ngarep Lexaria Bioscience Corp.|LEXX - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Lexaria Bioscience Corp.|LEXX - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Lexaria Bioscience|LEXX - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan lexariabioscience.com|LEXX - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Lexaria Bioscience
- indikator dodolan lan pendapatan:
Analisis komprehensif perusahaan:Lexaria LEXX
Lexaria Bioscience is developing DehydraTECH technology while facing volatility in licensing revenues and fierce competition within the drug delivery sector. The market capitalization to expected revenue ratio, equal to 46.80, measures the premium for future growth, allowing investors to use the forward P/S parameter to filter out random market fluctuations and assess the fair value of the business relative to its potential sales.
Pesaing Lexaria Bioscience
Rasio rega marang prakiraan pendapatan Haleon HLN|Kenvue Inc - Rasio rega marang prakiraan pendapatan|Verona Pharma Corp - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Jyong Bio|LGND (Ligand Pharmaceuticals) - Multiplikator forward rega marang pendapatan|Kapitalisasi marang prakiraan pendapatan AMRX|PRGO (Perrigo) - Multiplikator Forward P/S|Multiplikator Forward P/S Alvotech S.A.|Rasio rega marang prakiraan pendapatan Liquidia Technologies (LQDA)|GLPG (Galapagos Corp) - Rega forward marang dodolan|Multiplikator Forward P/S ANIP (ANI Pharmaceuticals)|Rasio kapitalisasi marang dodolan sing dikarepake mannkindcorp.com (MNKD)|Amphastar Pharmaceuticals, Inc. - Multiplikator Forward P/S|PCRX - Multiplikator Forward P/S|SPRY (ARS Pharma) - Multiplikator forward rega marang pendapatan|Theravance Corp - Rega forward marang dodolan|AQST (Aquestive Therapeutics) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan SCPH|Multiplikator Forward P/S TECX|Rasio kapitalisasi marang dodolan sing dikarepake Tonix Pharma|Rasio rega marang prakiraan pendapatan China SXT Pharmaceuticals, Inc. SXTC|Eupraxia Pharmaceuticals, Inc. (EPRX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|BHST - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake invizyne.com EXOZ|ORMP: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Entera Bio|HYFT (MindWalk) - Multiplikator Forward P/S|ABVC BioPharma, Inc (ABVC) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S CPIX|QNTM - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan FibroGen FGEN|TELO: Kapitalisasi marang prakiraan pendapatan|Rani Therapeutics Inc - Multiplikator Forward P/S|Synergy CHC Corp (SNYR) - Multiplikator forward rega marang pendapatan|RLYB: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep pulmatrix.com (PULM)|Rasio rega marang prakiraan pendapatan Pheton Holdings Limited|Rasio rega marang prakiraan pendapatan APM|Multiplikator Forward P/S LYRA|IBO - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|TNF Pharmaceuticals, Inc. - Multiplikator forward rega marang pendapatan|YCBD: Kapitalisasi marang prakiraan pendapatan|PRFX: Multiplikator forward rega marang pendapatan|CYTO (Altamira Therapeutics) - Kapitalisasi marang prakiraan pendapatan|Lipella (LIPO) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan OPTN (OptiNose Corp)|PIRS (Pieris Pharmaceuticals) - Multiplikator Forward P/S|PROC: Rega forward marang dodolan|Multiplikator Forward P/S PTPI|Multiplikator Forward P/S Qilian International Holding Group (QLI)|Rasio rega marang prakiraan pendapatan ACELYRIN, Inc. SLRN|Rega forward marang dodolan TFFP
